Zydus is an innovation-led global healthcare provider that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide including over 1200 scientists engaged in research and is dedicated to creating healthier communities globally. With a strong research pipeline of NCEs, biologics and vaccines, the group became IndiaÍs first pharmaceutical company to launch its own indigenously researched therapy Lipaglyn which is also the worldÍs first approved therapy for diabetic dyslipidaemia. Exemptia, the worldÍs first biosimilar of Adalimumab is also a product of Zydus innovation. Zydus also collaborates with partners to support and make therapies affordable and accessible to communities across the world. As a leading healthcare provider, it aims to become a global research-based pharmaceutical company by 2020. For more details visit www.zyduscadila.com. Official Twitter handle: @ZydusUniverse